Australia has the highest rate of melanoma in the world. It is not a coincidence that it also has one of the largest outdoor workforces. For employers in construction, agriculture, mining, local government, and education, melanoma is not an abstract public health problem — it is an occupational hazard with real legal, financial, and human consequences.
This article covers what the evidence says about melanoma risk in outdoor workers, what Australian WHS law requires of employers, and what a robust health surveillance program looks like in practice.
Why outdoor workers are at elevated melanoma risk
Melanoma is caused by cumulative ultraviolet (UV) radiation damage to skin cells. Unlike some cancers, the relationship between exposure and risk is well-established and dose-dependent: the more UV a person is exposed to over their lifetime, the higher their risk.
Outdoor workers accumulate UV exposure at a rate that indoor workers simply do not. A construction labourer working full-time outdoors in Queensland receives an annual UV dose roughly ten times higher than an office worker in the same city. Over a twenty-year career, that gap compounds significantly.
77% of all occupational cancer claims in Australia are for skin cancer — the majority of which are among outdoor workers.
The industries most affected include:
- Construction and civil infrastructure
- Farming, horticulture, and agricultural services
- Mining and resources — particularly surface operations
- Local government field workers (parks, roads, waste, utilities)
- Education staff involved in outdoor supervision and sport
- Sports, recreation, and aquatic facility workers
What makes melanoma particularly concerning from a WHS perspective is its latency. The damage accumulates silently over years. Workers rarely present with symptoms until a lesion has progressed — by which point the prognosis, the treatment cost, and the workers’ compensation liability are all significantly worse.
The occupational cancer classification
UV radiation from solar exposure is classified as a Group 1 carcinogen by the International Agency for Research on Cancer (IARC). This is the highest classification — the same category as asbestos and benzene. It means the evidence for causation is conclusive.
This classification has direct implications for how employers should treat UV exposure under WHS legislation. A Group 1 carcinogen is not a residual risk to be managed with awareness campaigns. It is a confirmed occupational hazard requiring systematic controls, monitoring, and health surveillance — in the same way that noise-induced hearing loss is managed with audiometric testing, or chemical exposure is managed with biological monitoring.
Most Australian workplaces do not yet manage UV exposure at this standard. Sun safety programs typically stop at PPE, shade, and training. Health surveillance — the clinical monitoring of whether those controls have been effective — is rarely in place.
What WHS law requires for occupational UV exposure
Under the model Work Health and Safety Act, employers have a primary duty of care to ensure, so far as is reasonably practicable, that the health of their workers is not put at risk from work. For a hazard as significant and well-documented as UV radiation, this duty is difficult to discharge without a structured health monitoring program.
The WHS Regulations support this with specific provisions for health monitoring where workers are exposed to a hazard that carries a risk of health effects. Safe Work Australia’s guidance on occupational cancer lists UV radiation as a carcinogen requiring risk management, including consideration of health surveillance.
What ‘reasonably practicable’ looks like for UV exposure
For most outdoor workforces, a court or regulator assessing an employer’s duty of care would look for:
- Hazard identification — UV radiation documented as a workplace hazard in your risk register.
- Risk controls — evidence that elimination, engineering, administrative, and PPE controls are in place and maintained.
- Health monitoring — a structured program to assess whether controls are working and whether workers’ health has been affected.
- Records — documentation demonstrating that the program ran, workers participated, and outcomes were acted on.
Points one, two, and four are common in well-managed workplaces. Point three — clinical health monitoring — is the gap that most employers have not yet addressed.
What melanoma health surveillance looks like in practice
Health surveillance for melanoma risk means periodic clinical skin screening, reviewed by a qualified health practitioner, with documented outcomes. It is not a wellness check, a self-assessment form, or a first-aid skin check. It is occupational health monitoring conducted to a clinical standard.
Core elements of an effective program
- Periodic frequency — annual screening at a minimum; more frequent for higher-risk workers or those with a personal or family history.
- Clinical review — each screening reviewed by a registered nurse practitioner, with GP escalation for any identified concerns.
- Referral pathway — clinically flagged workers receive a GP-signed referral enabling a Medicare-covered specialist consultation.
- Documentation — a timestamped clinical record for every screening, stored securely and accessible to the worker.
- Employer reporting — aggregate data on participation rates and program activity, without disclosure of individual health information.
- Accessibility — the program must be accessible to all workers, across all sites and roster patterns, without requiring them to leave their worksite.
The accessibility requirement is often where traditional screening programs fall short. A mobile clinic visiting once a year, requiring workers to book an appointment during a specific window, will capture 30–50% of the workforce at best. A phone-based screening program that workers complete at a time and location of their choosing can achieve participation rates of 80% or higher — which matters both for worker health outcomes and for the employer’s compliance evidence.
The business case for proactive melanoma screening
Beyond legal compliance, there is a straightforward financial case for employers to implement melanoma screening.
Workers’ compensation costs
Advanced melanoma treatment is expensive. Surgery, immunotherapy, and ongoing specialist care for a late-stage diagnosis can generate workers’ compensation costs well above $100,000. A missed diagnosis caught late — where early screening could have enabled a simpler, cheaper intervention — creates both a cost liability and a legal exposure.
Lost time and productivity
Workers diagnosed with advanced melanoma face extended treatment periods and recovery time. Workforce disruption from serious illness is a real operational cost, particularly in industries where experienced outdoor workers are difficult to replace.
Incident prevention
Early detection is the most effective melanoma intervention available. A worker whose early-stage lesion is identified through a screening program — and who accesses treatment promptly — faces dramatically better outcomes than one whose diagnosis is delayed. The program cost per screening is trivial compared to the human and financial cost of a preventable advanced cancer.
Regulatory risk
WHS regulators and workers’ compensation tribunals pay close attention to whether employers have taken proactive steps to identify and manage occupational health risks. An employer who cannot demonstrate that health monitoring was in place is in a much weaker position if a claim or prosecution follows a melanoma diagnosis.
Getting started
Implementing a melanoma screening program for your workforce does not require a significant project. The key steps are:
- Identify your exposed workforce — any workers with regular, significant outdoor time are candidates for the program.
- Select a screening provider — one with clinical oversight, privacy-compliant data handling, and a referral pathway that meets Australian clinical standards.
- Communicate clearly — tell workers the program is available, that it is voluntary, and that their individual results go to them — not to you.
- Roll out consistently — phone-based programs can be deployed across multiple sites at once without coordinating clinic visits.
- Track participation — aggregate reporting lets you see where uptake is low and follow up accordingly.
- Maintain records — document the program’s operation, participation data, and any process improvements as evidence of your ongoing duty of care.
Skin cancer is the most preventable cancer in Australia. For employers with outdoor workforces, it is also one of the most significant occupational health obligations. A structured melanoma screening program is the clearest evidence that your organisation is taking that obligation seriously.